• Главная
  • NEW DAY MEDICINE
  • 3 (89) 2026
  • 80 -3 (89) 2026 - Khodjiyeva N.Sh. - MORPHOLOGICAL FEATURES OF THE SPLEEN TISSUE IN 3-MONTH-OLD WHITE HYBRID RATS WITH RENAL FAILURE DEVELOPED FOLLOWING CHEMOTHERAPY

80 -3 (89) 2026 - Khodjiyeva N.Sh. - MORPHOLOGICAL FEATURES OF THE SPLEEN TISSUE IN 3-MONTH-OLD WHITE HYBRID RATS WITH RENAL FAILURE DEVELOPED FOLLOWING CHEMOTHERAPY

MORPHOLOGICAL FEATURES OF THE SPLEEN TISSUE IN 3-MONTH-OLD WHITE HYBRID RATS WITH RENAL FAILURE DEVELOPED FOLLOWING CHEMOTHERAPY

Khodjiyeva N.Sh. - Bukhara State Medical Institute named after Abu Ali Ibn Sina

Resume

Under conditions of experimental chemotherapy-induced renal failure, the splenic tissue of 3-month-old white hybrid rats demonstrated significant morphological alterations. The spleen capsule and trabeculae were thickened, vascular wall permeability increased, and fibrinoid changes with features of hyalinosis were observed. In the PALS region, T-lymphoblast proliferation was noted, while the number of mature T and B lymphocytes decreased and macrophage activity was reduced. The red pulp was narrowed, with erythrocyte hemolysis and atrophy of splenic cords observed. These findings reflect the morphological and immunological status of the spleen in experimental chemotherapy-induced renal failure.

Keywords: renal failure, chemotherapy, white hybrid rats, spleen morphology, hypoxia, lymphocytes, pulp alterations.

First page

494

Last page

498

For citation:Khodjiyeva N.Sh. - MORPHOLOGICAL FEATURES OF THE SPLEEN TISSUE IN 3-MONTH-OLD WHITE HYBRID RATS WITH RENAL FAILURE DEVELOPED FOLLOWING CHEMOTHERAPY//New Day in Medicine 3(89)2026 494-498 https://newdayworldmedicine.com/en/new_day_medicine/3-89-2026

List of References

  1. Бахронов ЖЖ. Морфология почки и биохимические изменения крови при химиотерапии и токсическое поражение печени. Central Asian Journal of Medical and Natural Science. 2024.
  2. Громова ЕГ, Бирюкова ЛС, Джумабаева БТ, Курмуков ИА. Практические рекомендации по коррекции нефротоксичности противоопухолевых препаратов. Практические рекомендации RUSSCO, часть 2. Злокачественные опухоли. 2023.
  3. Громова ЕГ, и др. Коррекция нефротоксичности противоопухолевых препаратов. Злокачественные опухоли. 2023.
  4. Карабина ЕВ, Сакаева ДД, Липатов ОН. Безопасность применения противоопухолевых лекарственных препаратов «вне инструкции» в онкологии. Креативная хирургия и онкология. 2024.
  5. Колина ИБ, Бобкова ИН. Поражение почек при злокачественных образованиях. Клиницист. 2014.
  6. Маковецкая ГА, Мазур ЛИ, Балашова ЕА, Шамин АВ, Терехин СС, Баринов ВН, Баранникова ЕА. Нефрологические риски в педиатрической онкологии. Нефрология. 2019.
  7. Салахутдинова ЛМ. Кардиотоксичность при лечении онкологических пациентов (обзор литературы). Поволжский онкологический вестник. 2022.
  8. Сапожников КВ, и др. Профилактика фебрильной нейтропении у онкологических пациентов: данные реальной клинической практики. Современная онкология. 2023.
  9. Banach M, Juranek JK, Zygulska AL. Chemotherapy-induced neuropathies—a growing problem for patients and health care providers. Brain Behav. 2017;7(1):e00558. doi:10.1002/brb3.558.
  10. Hałka J, et al. The nephrotoxicity of drugs used in causal oncological therapies. Curr Oncol. 2022;29(2):1287–1300. doi:10.3390/curroncol29020107.
  11. Weng Q, et al. Catalytic activity tunable ceria nanoparticles prevent chemotherapy-induced acute kidney injury without interference with chemotherapeutics. Nat Commun. 2021;12:1436. doi:10.1038/s41467-021-21796-4.
  12. World Health Organization. News release, 01 Feb 2024. Available from: https://www.who.int/ru/news/item/01-02-2024

    file

    download